The sustainability question: what ethical, affordable, scalable, effective, safe, ecological means for this field

Reading time: 6 minutes

The previous article surveyed the applications of developmental and stem cell science: disease modelling, therapy, reproduction, species preservation, food production, and ageing research. Each is at a different stage of development. Each faces distinct scientific and technical barriers. But they share a common question that is rarely asked with enough rigour: are the technologies being developed to serve these applications sustainable?

Not sustainable in the narrow environmental sense, though that is part of it. Sustainable in the broader sense of whether they can achieve and maintain real-world impact at the scale needed to matter. This article proposes a framework for thinking about that question, one that runs through all the content on this site.

The six facets

For a stem cell technology to be genuinely transformative, it must address six facets simultaneously. These are not aspirations. They are requirements. A technology that is effective but unaffordable does not reach patients. One that is scalable but unsafe does not survive regulation. One that is ethical and affordable but ecologically damaging creates a new problem while solving another.

Sustainability requires that technology be ethical, affordable, scalable, effective, safe, and ecological.

Ethical. This concerns how cells and tissues are obtained, how they are used, and who benefits. For embryonic stem cells, the ethical dimension has historically centred on the use of human embryos. For iPSCs, it shifts to questions of consent, data privacy, and the ownership of cell lines derived from patient material. For conservation applications, it extends to whether intervening in the biology of an endangered species is justified and who decides. For cultured meat, it includes whether the elimination of animal slaughter is offset by other concerns, such as the use of animal-derived components in culture media [1]. Ethical assessment is not a box to tick at the start of a project. It is a consideration whose tenets must be articulated and defended and that must be revisited as a technology develops and its applications expand.

Affordable. A therapy that costs hundreds of thousands of pounds per patient is not a solution for a disease that affects millions. A cultured meat product that costs orders of magnitude more than conventional meat is not a food system. Affordability is not just about the price of the final product. It includes the cost of raw materials, manufacturing infrastructure, quality control, regulatory compliance, and distribution. Many stem cell technologies are currently expensive because they rely on small-batch, manually intensive processes using costly reagents. Reducing cost requires innovation across the entire supply chain, from media formulation to process automation to quality assurance [2].

Scalable. Scalability is connected to affordability but not identical to it. A process can be cheap per unit at small scale and fail entirely at large scale. Stem cell manufacturing faces specific scaling challenges: cells in suspension culture experience shear stress in bioreactors, nutrient gradients become heterogeneous at larger volumes, and the risk of contamination increases with production size. Technologies that work at millilitre scale in a research laboratory may not function at litre scale in a manufacturing facility [3]. Scalability must be considered during process development, not as an afterthought once a product is in clinical trials. The Pillar 2 article on scale-up examines these manufacturing-scale challenges in detail.

Effective. Does the technology do what it is supposed to do? For a therapy, this means demonstrating clinical benefit in controlled trials. For a tool, it means reliably performing its specified function across different users, cell lines, and contexts. For a food product, it means delivering the nutritional and sensory properties consumers expect. Effectiveness is the most obvious requirement but also one of the hardest to prove, particularly for novel biological products where the mechanisms of action may be incompletely understood and the endpoints for measuring success may be ambiguous [4].

Safe. Safety encompasses risks to patients, operators, and the broader public. For cell therapies, this includes the risk of tumour formation from undifferentiated or genetically abnormal cells, the risk of immune rejection, and the risk of transmitting infectious agents, including unconventional agents such as prions [5]. For manufacturing processes, it includes operator safety in environments handling biological materials. For food products, it includes the safety of the production process and the final product. Safety assessment must be proportionate to the intended use: the standards for a clinical product are different from those for a research reagent, but both must be defined and met.

Ecological. The environmental impact of stem cell technologies is rarely discussed but is becoming increasingly relevant. Cell culture is resource-intensive: it requires controlled environments, large volumes of media, single-use plastics, and energy for temperature control and processing. At industrial scale, the carbon footprint and waste generation of cell manufacturing could become significant [6]. For applications such as cultured meat, ecological sustainability is a central part of the value proposition and must be demonstrated with data, not assumed. For conservation applications, the ecological context is the very purpose of the technology.

Why all six matter at once

The temptation is to prioritise one or two facets and defer the others. A research group may focus on effectiveness and leave affordability to someone else. A startup may focus on scalability and assume that safety will be addressed during regulatory review. An investor may focus on market size and treat ethics as a public relations concern.

This approach leads to predictable failures. Technologies that are effective in the laboratory but cannot be manufactured affordably stall in translation. Products that scale but lack adequate safety data are rejected by regulators. Innovations that ignore ecological impact face growing scrutiny from funders, consumers, and policymakers.

The six-facet framework I propose is designed to force early consideration of all dimensions. It does not require that every technology scores perfectly on all six from the outset. It does require that developers, funders, and regulators assess where a technology stands on each, where the gaps are, and what it would take to close them.

Applying the framework

In future articles on this site, we will apply this framework to specific technologies and application areas. We will use it to assess the state of the art in ancillary technologies for stem cell science, to evaluate emerging applications in species preservation and ageing research, and to examine what sustainability means in practice for GMP manufacturing. Pillar 2 begins this assessment by examining the systemic reasons ancillary technologies for stem cell science fail, from reproducibility to scale-up to characterisation gaps.

The framework will also inform a scoring method for evaluating the potential of stem cell technologies for real-world impact, which we will develop in Pillar 6 of this series.

For now, the key point is this: transformative impact in developmental and stem cell science is not achieved by solving any single problem in isolation. It requires progress across all six facets in parallel. The technologies, tools, and approaches that will ultimately succeed are those that are designed with this breadth of requirements in mind from the beginning.

References

[1] Hyun I, Wilkerson A, Johnston J. Embryology policy: revisit the 14-day rule. Nature. 2016;533(7602):169-171. DOI: 10.1038/533169a

[2] Lipsitz YY, Timmins NE, Zandstra PW. Quality cell therapy manufacturing by design. Nat Biotechnol. 2016;34(4):393-400. DOI: 10.1038/nbt.3525

[3] Kropp C, Massai D, Zweigerdt R. Progress and challenges in large-scale expansion of human pluripotent stem cells. Process Biochem. 2017;59:244-254. DOI: 10.1016/j.procbio.2016.09.032

[4] Yamanaka S. Pluripotent stem cell-based cell therapy: promise and challenges. Cell Stem Cell. 2020;27(4):523-531. DOI: 10.1016/j.stem.2020.09.014

[5] De Sousa PA, Ritchie D, Green A, Chandran S, Knight R, Head MW. Renewed assessment of the risk of emergent advanced cell therapies to transmit neuroproteinopathies. Acta Neuropathologica. 2019;137(3):363-377. DOI: 10.1007/s00401-018-1941-9

[6] Allan SJ, De Bank PA, Ellis MJ. Bioprocess design considerations for cultured meat production with a focus on the expansion bioreactor. Front Sustain Food Syst. 2019;3:44. DOI: 10.3389/fsufs.2019.00044

About StemCells.Help

StemCells.Help is an advisory consultancy that aids innovation and real-world impact of life science applications built on developmental and stem cell biology. Founded by Dr Paul De Sousa, it draws on over four decades of experience spanning early embryo development, animal cloning, pluripotent stem cell manufacturing, and technology commercialisation. If you build tools for these domains or work in an emerging application where the biology is the enabling technology, StemCells.Help can provide experienced scientific counsel to ground your decisions. To discuss your needs, talk to Paul.

ORCID: 0000-0003-0745-2504

Web: stemcells.help